Literature DB >> 8799234

The incidence of scintigraphically viable and nonviable tissue by rubidium-82 and fluorine-18-fluorodeoxyglucose positron emission tomographic imaging in patients with prior infarction and left ventricular dysfunction.

R T Go1, W J MacIntyre, S A Cook, D R Neumann, R C Brunken, G B Saha, D A Underwood, T H Marwick, E Q Chen, J L King, S Khandekar.   

Abstract

BACKGROUND: Although reversible perfusion defects, perfusion-metabolism mismatch and match patterns are important for differentiating viable from nonviable myocardium, the frequency of these scintigraphic patterns has not been reported. The study objective was to establish the incidence of these scintigraphic patterns to estimate the clinical need for metabolic positron emission tomography for evaluating tissue viability in patients with prior myocardial infarction (MI). METHODS AND
RESULTS: 82Rb perfusion images were interpreted to identify reversible or irreversible defects, followed by determination of their 18F-fluorodeoxyglucose (18F-FDG) uptake pattern. In 155 patients with prior MI, analysis of 613 abnormal segments showed reversible perfusion defects in 13%. The 87% irreversible defects, 18% showed perfusion-metabolism mismatch, whereas 69% showed the match pattern. Reversible perfusion defects and perfusion-metabolism mismatches were noted in 20% (31/155) and 29% (45/155) of patients, respectively, whereas the match pattern was noted in 51% (79/155) of patients.
CONCLUSION: Irreversible perfusion defects were common in our patients with prior MI, and distinction between viable and nonviable tissue was not possible by perfusion imaging alone. The identification of hibernating myocardium was possible only with the additional 18F-FDG imaging in about one third of patients. This indicates a significant clinical demand for 18F-FDG imaging that identifies patients who will benefit from revascularization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799234     DOI: 10.1016/s1071-3581(96)90001-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  24 in total

1.  Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction.

Authors:  T Carrel; R Jenni; S Haubold-Reuter; G von Schulthess; M Pasic; M Turina
Journal:  Eur J Cardiothorac Surg       Date:  1992       Impact factor: 4.191

2.  Rest-injected thallium-201 imaging for assessing viability of severe asynergic regions.

Authors:  T Mori; K Minamiji; H Kurogane; K Ogawa; Y Yoshida
Journal:  J Nucl Med       Date:  1991-09       Impact factor: 10.057

Review 3.  Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose.

Authors:  R J Gropler
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

4.  The hibernating myocardium.

Authors:  S H Rahimtoola
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

5.  Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction.

Authors:  J A Leppo; J O'Brien; J A Rothendler; J D Getchell; V W Lee
Journal:  N Engl J Med       Date:  1984-04-19       Impact factor: 91.245

6.  Hibernating myocardium versus scar: severity of irreversible decreased myocardial perfusion in prediction of tissue viability.

Authors:  R T Go; W J MacIntyre; G B Saha; S A Cook; D R Neumann; E Q Chen; D A Underwood; T Kaczur
Journal:  Radiology       Date:  1995-01       Impact factor: 11.105

Review 7.  A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina.

Authors:  S H Rahimtoola
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

8.  Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography.

Authors:  R S Gibson; D D Watson; G B Craddock; R S Crampton; D L Kaiser; M J Denny; G A Beller
Journal:  Circulation       Date:  1983-08       Impact factor: 29.690

9.  Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography.

Authors:  D Eitzman; Z al-Aouar; H L Kanter; J vom Dahl; M Kirsh; G M Deeb; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

10.  Glucose metabolism in relation to perfusion in patients with ischaemic heart disease.

Authors:  N Takahashi; N Tamaki; M Kawamoto; Y Yonekura; Y Magata; R Nohara; S Sasayama; J Konishi; K Yamamoto; Y Ishii
Journal:  Eur J Nucl Med       Date:  1994-04
View more
  5 in total

1.  Exercise-induced myocardial ischemia: can this be imaged with F-18-fluorodeoxyglucose?

Authors:  D Jain; P H McNulty
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

2.  Ischemic changes on rubidium-82 positron emission tomography imaging are associated with left ventricular functional and volumetric change independent of metabolic properties and echocardiographic functional variables in ischemic cardiomyopathy.

Authors:  Raymond C Wong; Manuel D Cerqueira; Richard C Brunken
Journal:  Int J Cardiovasc Imaging       Date:  2011-11-11       Impact factor: 2.357

3.  Combined CT-PET criteria for myocardial viability and scar: a preliminary report.

Authors:  Ching-yee Oliver Wong; Visweswara Rao Tatini; Kostaki Bis
Journal:  Int J Cardiovasc Imaging       Date:  2004-12       Impact factor: 2.357

Review 4.  Reversible congestive heart failure caused by myocardial hibernation.

Authors:  J M Wilson
Journal:  Tex Heart Inst J       Date:  1999

5.  Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance study.

Authors:  Christos V Bourantas; Nikolay P Nikitin; Huan P Loh; Elena I Lukaschuk; Nassar Sherwi; Ramesh de Silva; Ann C Tweddel; Mohamed F Alamgir; Kenneth Wong; Sanjay Gupta; Andrew L Clark; John Gf Cleland
Journal:  J Cardiovasc Magn Reson       Date:  2011-09-21       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.